Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. The opening of the NMDA receptor ion channel requires occupation of two distinct binding sites, the glutamate site and the glycine site. It has been shown that D-serine, rather than glycine, can trigger the physiological NMDA receptor function. D-serine is a product of the activity of a specific enzyme, serine racemase (SR), which was identified a decade ago. SR has therefore emerged as a new potential target for the NMDA-receptor-based diseases. There is evidence linking increased levels of D-Ser to amyotrophic lateral sclerosis and Alzheimer's disease and decreased concentrations of D-serine to schizophrenia. SR is a pyridoxal-5'-phosphate dependent enzyme found in the cytosol of glial and neuronal cells. It is activated by ATP, divalent cations like Mg(2+) or Ca(2+), and reducing agents. This paper reviews the present literature on the activity and inhibition of mammalian SRs. It summarizes approaches that have been applied to design SR inhibitors and lists the known active compounds. Based on biochemical and docking analyses, i) we delineate for the first time the ATP binding site of human SR, and ii) we suggest possible mechanisms of action for the active compounds. In the end, we discuss the SR features that make the discovery of its inhibitors a challenging, yet very important, task of medicinal chemistry.
Glutamate carboxypeptidase
II
(
GCPII
), also known as prostate‐specific membrane antigen (
PSMA
) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate.
GCPII
expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore,
GCPII
represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse
GCPII
activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human
GCPII
orthologs remains lacking. In this study, we prepared extracellular mouse
GCPII
and compared it with human
GCPII
. We found that mouse
GCPII
possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of
GCPII
inhibitors, we discovered that inhibition constants are generally similar for mouse and human
GCPII
. Furthermore, we observed highest expression of
GCPII
protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect
GCPII
in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse
GCPII
can approximate human
GCPII
in drug development and testing. On the other hand, significant differences in
GCPII
tissue expression must be taken into account when developing novel
GCPII
‐based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.
In this study, we provide the first evidence characterizing the reproductive tissue phenotype of PSMA/GCPII-deficient mice. These findings will help lay the groundwork for future studies to reveal PSMA/GCPII function in human reproduction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.